{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:29:22Z","timestamp":1777858162116,"version":"3.51.4"},"reference-count":59,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2003,6]]},"abstract":"<jats:p>\n                    Drugs that enhance \u03b3-aminobutyric acid (GABA) activity by interacting at post-synaptic GABA\n                    <jats:sub>A<\/jats:sub>\n                    receptors have long been used as hypnotics, sedatives, tranquillizers and anticonvulsants. In this category, benzodiazepines rapidly gained pride of place, replacing barbiturates and becoming the most commonly prescribed of all drugs in the Western world in the 1970s. However, problems such as dependence and withdrawal reactions became apparent in the 1980s, and it seemed that the usefulness of drugs with this mode of action was limited. Recently, focus has shifted to a new group of drugs with GABA-ergic actions mediated through various mechanisms not directly involving the GABA\n                    <jats:sub>A<\/jats:sub>\n                    receptor. These drugs include gabapentin, vigabatrin, tiagabine, lamotrigine, pregabalin and others. Although originally developed as anticonvulsants for epilepsy, they appear to have wider applications for use in affective disorders, especially bipolar depression, anxiety disorders and pain conditions. The current information on the properties and therapeutic potential of this new generation of GABA-ergic drugs is reviewed. It remains to be seen whether long-term use leads to tolerance, dependence and withdrawal or discontinuation reactions.\n                  <\/jats:p>","DOI":"10.1177\/0269881103017002004","type":"journal-article","created":{"date-parts":[[2003,7,3]],"date-time":"2003-07-03T17:45:03Z","timestamp":1057254303000},"page":"174-178","source":"Crossref","is-referenced-by-count":66,"title":["GABA-Ergic Drugs: Exit Stage Left, Enter Stage Right"],"prefix":"10.1177","volume":"17","author":[{"given":"Heather","family":"Ashton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Newcastle upon Tyne, Royal                        Victoria Infirmary, Newcastle upon Tyne, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,6,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.157.2.232"},{"key":"atypb2","unstructured":"Ashton H (2002) Benzodiazepine abuse. In Caan W, de Belleroche J (eds), Drink, drugs and dependence: from science to clinical practice. Routledge, London"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90581-2"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1128(199903)19:2<149::AID-MED3>3.0.CO;2-B"},{"key":"atypb5","unstructured":"Calabrese J R, Shelton M D, Rapport D J, Kimmell S E, Elhaj O (2002) Long-term treatment of bipolar disorder with lamotrigine . J Clin Psychiatry 63 (Suppl 10): 22-22"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-19836"},{"key":"atypb7","unstructured":"Carter R B, Wood P L, Wieland S, Hawkinson J E, Belleli D, Lambert J J, White H S, Wolf H H, Mersedeghi S, Tahir S H, Bolger N B, Lan N C, Gee K W (1997) Characterisation of the anticonvulsant properties of ganaxolone (CCD 1042 3alphahydroxy-3beta-methyl-5alpha-pregnan-20one), a selective high affinity, steroid modulator of the gamma-aminobutyric acis (A) receptor . J Pharmacol Exp Ther 280: 1284-1295"},{"key":"atypb8","doi-asserted-by":"crossref","unstructured":"Cavallaro R, Regazzetti M G, Smeralid E (1993) Tolerance and withdrawal with zolpidem . Lancet 342: 374-375","DOI":"10.1016\/0140-6736(93)91522-N"},{"key":"atypb9","unstructured":"Cochrane Database Systematic Review (2002) Antidepressant and benzodiazepine for major depression (1): CD00 1026"},{"key":"atypb10","unstructured":"Committee on Safety of Medicines (1988) Benzodiazepines, dependence and withdrawal symptoms . Curr Problems 21: 1-2"},{"key":"atypb11","unstructured":"Committee on Safety of Medicines (1998) Vigabatrin (Sabril) and visual field defects . Curr Prob Pharmacovig 24: 1-1"},{"key":"atypb12","doi-asserted-by":"crossref","unstructured":"Covington E C (1998) Anticonvulsants for neuropathic pain and detoxification . Cleve Clin J Med 65 (Suppl 1): S121-S129","DOI":"10.3949\/ccjm.65.s1.21"},{"key":"atypb13","unstructured":"Crawford P (1994) Managing therapy and possible problems , Prescriber 5(4): 31-36"},{"key":"atypb14","doi-asserted-by":"crossref","unstructured":"Crockford D, Cambell B (2001) Gabapentin use in benzodiazepine dependence and detoxification . Can J Psychiatry 46: 287-287","DOI":"10.1177\/070674370104600315"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115050-00001"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(96)00005-X"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.4.1025"},{"key":"atypb18","doi-asserted-by":"crossref","unstructured":"Drug and Therapeutics Bulletin (1980) The CRM on benzodiazepines . Drug Therap Bull 24: 97-98","DOI":"10.1136\/dtb.18.25.97"},{"key":"atypb19","doi-asserted-by":"crossref","unstructured":"Eke T, Talbot J F, Lawdon M C (1977) Severe persistent visual field constriction associated with vigabatrin . Br Med J 314: 180-181","DOI":"10.1136\/bmj.314.7075.180"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1159\/000026536"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703794"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200012000-00004"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1159\/000468500"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0111"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1124\/mol.61.6.1377"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7125.117"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00050-X"},{"key":"atypb28","doi-asserted-by":"crossref","unstructured":"Kasper S, Blagdon M, Seghers S, Voorman A, Volz H P, Geniaux A, Struh N, Marchand A, Malsonobe P, Mikkelsen H (2002) A placebo-controlled study of pregabalin and venlafaxine treatment of GAD . Poster presented at Annual Meeting of the American Psychiatric Association, Philadelphia, PA","DOI":"10.1016\/S0924-977X(02)80535-1"},{"key":"atypb29","unstructured":"Lader M (1987) Long-term benzodiazepine use and psychological functioning . In Freeman H, Rue Y (eds), The benzodiazepines in current clinical practice. International Congresss and Symposium Series, Royal Society of Medicine Services, London and New York"},{"key":"atypb30","unstructured":"Lader M W, Petursson H (1981) Benzodiazepine derivatives - side effects and dangers . Biol Psychiatry 16: 1195-1212"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)05035-6"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1986.tb03573.x"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.62.4.372"},{"key":"atypb34","doi-asserted-by":"crossref","unstructured":"Lucki I, Rickels K, Geller A M (1986) Chronic use of benzodiazepines and psychomotor and cognitive test performance . Psychopharmacology 88: 426-433","DOI":"10.1007\/BF00178503"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216080-00004"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199818040-00004"},{"key":"atypb37","doi-asserted-by":"crossref","unstructured":"Olajide D, Lader M (1987) A comparative study of the efficacy of buspirone in relieving benzodiazepine withdrawal symptoms . J Clin Psychopharmacol 7: 11-15","DOI":"10.1097\/00004714-198702000-00003"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199908000-00010"},{"key":"atypb39","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2000.20305.x"},{"key":"atypb40","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200008000-00011"},{"key":"atypb41","unstructured":"Perry E, Young A H (2002) Neurotransmitter networks. In Perry E, Ashton H, Young A (eds) Neurochemistry of consciousness. John Bejamins Publishing Company, Amsterdam and Philadelphia"},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1192\/apt.5.2.96"},{"key":"atypb43","doi-asserted-by":"crossref","unstructured":"Rao G P, Fat F A, Kyle G (1998) Study is needed of visual field defects associated with any long term antiepileptic drug . Br Med J 317: 206-206","DOI":"10.1136\/bmj.317.7152.206"},{"key":"atypb44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1992.tb04473.x"},{"key":"atypb45","unstructured":"Rickels K, Pollack M H, Lydiard R B, Bielski R J, Feltner D E, Pande A C, Kavoussl R J (2002) Efficacy and safety of pregabalin and alprazolam in generalized anixety disorder . Poster presented at Annual Meeting of the American Psychiatric Association, Philadelphia, PA"},{"key":"atypb46","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.9.758"},{"key":"atypb47","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90769-Y"},{"key":"atypb48","doi-asserted-by":"crossref","unstructured":"Ryback R, Ryback L (1997) Gabapentin for behavioural dyscontrol . Am J Psychiatry 152: 1399-1399","DOI":"10.1176\/ajp.152.9.1399a"},{"key":"atypb49","unstructured":"Selak I (2001) Pregabalin (Pfizer) . Curr Opin Invest Drugs 2: 828-834"},{"key":"atypb50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1996.tb03190.x"},{"key":"atypb51","doi-asserted-by":"publisher","DOI":"10.1007\/BF02805968"},{"key":"atypb52","doi-asserted-by":"crossref","unstructured":"Soderpalm B (2002) Anticonvulsants: aspects of their mechanisms of action . Eur J Pain 6 (Suppl A): 3-9","DOI":"10.1053\/eujp.2001.0315"},{"key":"atypb53","doi-asserted-by":"crossref","unstructured":"Stanton S P, Keck P E, McElroy S L (1997) Treatment of acute mania with gabapentin . Am J Psychiatry 154: 287-287","DOI":"10.1176\/ajp.154.2.287a"},{"key":"atypb54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.8.708"},{"key":"atypb55","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00084-3"},{"key":"atypb56","doi-asserted-by":"crossref","unstructured":"Tyrer P, Rutherford D, Huggett T (1981) Benzodiazepine withdrawal symptoms and propranolol , Lancet 1: 520-522","DOI":"10.1016\/S0140-6736(81)92861-0"},{"key":"atypb57","unstructured":"Wheeler G (2002) Gabapentin (Pfizer) . Curr Opin Invest Drugs 3: 470-477"},{"key":"atypb58","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0402"},{"key":"atypb59","doi-asserted-by":"crossref","unstructured":"Young A, Haddad P (2000) Discontinuation symptoms and psychotropic drugs . Lancet 355: 1184-1184","DOI":"10.1016\/S0140-6736(05)72262-5"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881103017002004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881103017002004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:08:41Z","timestamp":1777507721000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881103017002004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["10.1177\/0269881103017002004"],"URL":"https:\/\/doi.org\/10.1177\/0269881103017002004","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}